Chemosensitizers can improve the therapeutic index of chemotherapy and overcome treatment resistance. Successful translation of chemosensitizers depends on the development of strategies that can preferentially deliver chemosensitizers to tumors while avoiding normal tissue. We hypothesized that nanoparticle (NP) formulation of chemosensitizers can improve their delivery to tumors which can in turn improve their therapeutic index. To demonstrate the proof of principle of this approach, we engineered NP formulations of two chemosensitizers, the PI3-kindase inhibitor wortmanin (Wtmn) and the PARP inhibitor olaparib. NP Wtmn and NP olaparib were evaluated as chemosensitizers using lung cancer cells and breast cancer cells respectively. We found Wtmn to be an efficient chemosensitizer in all tested lung-cancer cell lines reducing tumor cell growth between 20 and 60% compared to drug alone. NP formulation did not decrease its efficacy in vitro. Olaparib showed less consistent chemosensitization as a free drug or in NP formulation. NP Wtmn was further evaluated as a chemosensitizer using mouse models of lung cancer. We found that NP Wtmn is an effective chemosensitizer and more effective than free Wtmn showing a 32% reduction in tumor growth compared to free Wtmn when given with etoposide. Importantly, NP Wtmn was able to sensitize the multi-drug resistant H69AR cells to etoposide. Additionally, the combination of NP Wtmn and etoposide chemotherapy did not significantly increase toxicity. The present study demonstrates the proof of principle of using NP formulation of chemosensitizing drugs to improve the therapeutic index of chemotherapy.
Introduction
Chemotherapy is a key component of cancer treatment, and improvement in its therapeutic index can directly translate into increase in survival in cancer patients. 1 Because of its importance, there has been long standing interest in the development of novel approaches to improve the therapeutic index of chemotherapy. One strategy is to utilize chemosensitizers, NP therapeutic carriers possess several important characteristics that are well-suited for the delivery of chemosensitizers. First, NPs preferentially accumulate in tumors through the enhanced permeability and retention (EPR) effect, leading to high intratumoral drug concentrations. 4, 5 A significant increase in therapeutic efficacy can also lead to reductions in chemotherapy doses, which in turn would reduce treatment toxicity. Second, NPs have reduced permeability to normal vasculature and capillaries, thus leading to lower drug dose to normal tissues such as skin, lung, and heart when compared to their small molecule counterparts. 6 The advantages of NP biodistribution are illustrated in Figure 1 . Third, many NP platforms allow slow and controlled drug delivery. Such prolonged release can increase the synergistic effects between chemosensitizers and chemotherapy. Because of such unique properties we hypothesized that NP delivery of chemosensitizers can improve the therapeutic efficacy of chemotherapy without increasing its toxicity.
To explore our hypothesis and to demonstrate the proof of principle of using NP to deliver chemosensitizers, we utilized the chemosensitizers olaparib and Wtmn as model drugs.
Olaparib is a PARP inhibitor and has been shown to sensitize breast cancer cells to chemotherapy. 7 Wtmn is a potent inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and related proteins and is known to sensitize different types of tumor cells to treatment. 8, 9, 10 In this study, we evaluated NP formulations of olaparib and Wtmn as chemosensitizers using breast cancer and lung cancer (both small cell and non-small cell lung cancer) as tumor models. We compared the therapeutic effects of several chemotherapeutics with and without NP chemosensitizers. We also examined the toxicity profile of chemotherapy treatment with and without NP Wtmn.
Experimental
Materials. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy (polyethylene glycol)
2000 (DSPE-PEG2000-COOH) and the cross-linkable lipid (1-palmitoyl-2-(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine) (PTPC) were obtained from Avanti Polar Lipids (Alabaster, AL). Docetaxel (Dtxl), wortmannin (Wtmn), etoposide and gemcitabine hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO). Olaparib was purchased For in vivo studies, AUC was calculated for each cohort. We then statistically compared tumor growth curves with Wilcoxon rank-sum test (using Van der Waerden normal scores).
Two-sided P values are reported. These analyses were performed using R statistical software, version 3.1.1. In H460 cells and H23 cells, NP Wtmn resulted in similar or significantly lower survival rates than free Wtmn in combination with all three chemotherapeutics. Wtmn also functioned as a chemosensitizer in the SCLC H69AR cells (Figure 3c ). As expected, these cells were chemoresistant and there was no significant main effect of chemotherapy on ANOVA. However, they were sensitive to Wtmn and the combination of Wtmn and chemotherapy was more effective than chemotherapy alone.
Results and Discussion

NP
Olaparib is a demonstrated chemosensitizer which has been used in clinical trials for patients with BRCA mutated breast and ovarian cancers [12] [13] [14] . We chose breast cancer as a disease model to study NP olaparib as a chemosensitizer. Breast cancer cell lines, Hs578T and HCC38, were treated with NP or free olaparib in combination with chemotherapeutics. As seen in Figure   4a , Hs578T cells show varied results. Hs578T cells were sensitive to both olaparib and chemotherapy showing 10-30 percent decreases in survival to either (P<0.001 for main effects of We studied NP Wtmn's efficacy as a chemosensitizer using mice bearing H69AR xenografts. As seen in Figure 5 , the combination of NP Wtmn and etoposide significantly delayed tumor growth when compared to that of free Wtmn and etoposide or etoposide treatment without chemosensitization. High-dose etoposide alone was ineffective as a treatment. We also confirmed that NP Wtmn was more effective than free Wtmn as a chemosensitizer (P <0.03).
NP formulation of Wtmn decreases hepatotoxicity with chemotherapy. Although our previous work has shown that NP delivery of Wtmn minimized its hepatoxicity 11 , hepatotoxicity remains a potential concern when the drug is given in combination with another chemotherapy agent. Hence, we studied the hepatotoxicity profile of Wtmn and etoposide in vivo. Results of hepatotoxicity are seen in Figure 6 . As expected, the treatment regimen of free Wtmn and etoposide showed high levels of hepatotoxicity (AST: 302.5 ± 49.1 (normal range: 40-50 U/L)) which were significantly greater than all other treatment cohorts (P<0.05 for all). In contrast, the addition of NP Wtmn to free etoposide did not significantly increase AST or ALT levels compared to etoposide alone.
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Nanoscale Accepted Manuscript NP Wtmn prevents activation of DNA repair pathways. To confirm that the molecular mechanism of the Wtmn NP chemosensitization is indeed through prevention of DNA repair, we also performed western blot analysis of Wtmn targets which are thought to play a key role in DNA repair. [15] [16] As seen in Figure 7 , H460 cells that were treated with chemotherapy had activation of pDNA-PKcs, pAKT and pmTOR (another important signaling pathway). The activation of pDNA-PKcs and pAKT were inhibited by Wtmn or NP Wtmn. The inhibition from NP Wtmn or free Wtmn was much less for pmTOR, suggesting that the main mechanism of chemosensitization is through the inhibition of pDNA-PKcs and pAKT.
Discussion
The development of chemosensitizers can improve chemotherapy treatment and overcome chemoresistance, a major obstacle in cancer treatment. A key impediment to the clinical translation of chemosensitizers has been the lack of targeted delivery of these agents to tumors to avoid the sensitization of normal cells to chemotherapy. As discussed above, lipid-polymer NPs like those used in these experiments preferentially accumulate in tumors. We believe advances in NP drug delivery offer a unique opportunity. Our current study aims to demonstrate the proof of principle of using NPs to deliver chemosensitizers.
In this study, we focused on two chemosensitizers: Wtmn and olaparib. Wtmn has broad activity against many signaling molecules (including PI3K, PI3KK, and DNA-PK) [17] [18] [19] and can affect both tumor cells and normal tissue cells. In contrast, olaparib mainly inhibits PARP 20 and has been shown to have limited systemic toxicity in clinical trials. [12] [13] [14] By engineering and evaluting NP formulations of both of these chemosensitizers, we aimed to demonstrate that NP delivery improves chemosensitizers' efficacy without significantly increasing toxicity. In vitro evaluation of NP Wtmn showed that it is an effective chemosensitizer and more effective than The results on NP olaparib were mixed. In Hs578T cells we observed that NP olaparib was more effective than free olaparib only when it is combined with gemcitabine. Olaparib did not sensitize the tumor cells to etoposide or docetaxel. In HCC38 cells, free olaparib was an effective chemosensitizer but NP olaparib was not. Our findings showed that NP formulation of olaparib can improve its efficacy as a chemosensitizer in certain selected situations but not broadly as Wtmn. There are several reasons for the lack of efficacy of olaparib. First, despite the high enthusiasm for PARP inhibition as a strategy to improve chemotherapy, preclinical and clinical results have thus far been largely disappointing 12, 21 . Therefore, NP delivery may not be able to improve the therapeutic efficacy. Wtmn on the other hand is a potent inhibitor of PI3K
and affects a broad range of signaling pathways. Thus, it is a better chemosensitizer. As a result, we focused on the in vivo evaluation of NP Wtmn as a chemosensitizer.
Using mice bearing H69AR xenografts we demonstrated that NP Wtmn is a potent chemosensitizer and is more effective than free Wtmn. As predicted, this drug resistant lung 
